Alpelisib - Latest Advances

Alpelisib-induced severe interstitial lung disease: case report.

Journal: Journal of chemotherapy (Florence, Italy)

Published: January 02, 2026

Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.

Journal: Science translational medicine

Published: December 17, 2025

Structure-Guided Design of a Highly Selective PI3Kα Inhibitor Overcoming Metabolic Dysregulation with Potent Anti-breast Cancer Efficacy.

Journal: Journal of medicinal chemistry

Published: November 17, 2025

A Riskscore Model for Predicting Survival, Tumor Microenvironment, Immunotherapy and Drug Sensitivity of Lung Squamous Cell Carcinoma Based on PI3K/AKT/MTOR Pathway-Related Genes.

Journal: Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer

Published: November 10, 2025

Medical Therapies for Pediatric Lymphatic Malformations: A Systematic Review.

Journal: Journal of cutaneous medicine and surgery

Published: October 31, 2025

Erratum to "Autophagy inhibition enhances sensitivity of alpelisib in PI3K-mutated non-small cell lung cancer" [Biomed. Pharmacother. 192 (2025), 118620].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 17, 2025

Personalized drug screening and risk assessment in patient-derived gastroenteropancreatic neuroendocrine neoplasms.

Journal: The Journal of clinical endocrinology and metabolism

Published: October 15, 2025

Discovery of a novel PI3Kα inhibitor for breast cancer therapy via virtual screening method, molecular dynamics simulation and biological evaluation.

Journal: Journal of molecular graphics & modelling

Published: October 12, 2025

Adult-Onset Cervical Lymphatic Malformation: A Case Report.

Journal: Cureus

Published: September 30, 2025

USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer.

Journal: The Journal of clinical investigation

Published: September 24, 2025

Host PI3K inhibition via anti-cancer drug alpelisib influences Influenza A non-infectious particles and deletion-containing viral genomes.

Journal: Cell communication and signaling : CCS

Published: September 18, 2025

Complete Response With Alpelisib and Trastuzumab in a Patient With Estrogen Receptor-/Progesterone Receptor-Negative, Human Epidermal Growth Factor Receptor 2-Positive Refractory Metastatic Breast Cancer.

Journal: JCO precision oncology

Published: September 17, 2025